Minnesotans start promising new Alzheimer’s treatment
The Brief
- Kisunla was approved by the FDA in July for early stage Alzheimer’s Disease.
- Clinical trials showed it slowed the disease progression up to 35%.
- It works by cleaning out the damaging amyloid plaque in the brain.
GOLDEN VALLEY, Minn. (FOX 9) – Sixty-year-old Kathy Ingebrand sat in a chair in the Minneapolis Clinic of Neurology, getting her 4th monthly infusion of a promising new drug. She was diagnosed with Alzheimer’s in the fall of 2023. It remains to be seen if the damage to her brain can be slowed, but it’s clear she’s already felt a huge boost to her mental health.
“Well, it’s just a new beginning of hope,” she told us. “And what else can you do if you have a disease like this?”
Drug targets proteins that damage brain cells
What it is: The drug is called Kisunla and is given in monthly 30-minute infusions. In its clinical trials, it showed a clear effect on the study group versus the placebo group in the progression of Alzheimer’s symptoms.…